Target type: biologicalprocess
Any process that stops, prevents or reduces the frequency, rate or extent of telomeric DNA binding. [GO_REF:0000059, GOC:BHF, GOC:BHF_telomere, GOC:nc, GOC:TermGenie, PMID:24415760]
Negative regulation of telomeric DNA binding is a crucial process in maintaining genome stability and preventing premature senescence. Telomeres, the protective caps at the ends of chromosomes, are composed of repetitive DNA sequences and associated proteins. They are essential for maintaining chromosome integrity during DNA replication. However, with each cell division, telomeres progressively shorten, leading to replicative senescence.
To counteract this shortening, cells employ a telomerase enzyme that adds back telomeric DNA sequences. However, dysregulation of telomerase activity can lead to uncontrolled cell proliferation and cancer.
Negative regulation of telomeric DNA binding involves a complex interplay of proteins and signaling pathways that control the activity of telomerase and other factors that interact with telomeric DNA. Key proteins involved in this process include:
- **TRF1 and TRF2:** These proteins bind to telomeric DNA and act as negative regulators of telomerase activity. They can inhibit telomerase by directly interacting with its components or by recruiting other factors that repress telomerase activity.
- **TIN2:** This protein bridges TRF1 and TRF2 with other proteins involved in telomere maintenance, including TPP1 and POT1.
- **TPP1:** This protein acts as a scaffold for the telomere-binding complex and recruits POT1.
- **POT1:** This protein binds to single-stranded telomeric DNA and protects it from degradation.
Negative regulation of telomeric DNA binding also involves post-translational modifications of these proteins, such as phosphorylation and ubiquitination. These modifications can alter their activity and interactions with other proteins.
In addition to these protein-mediated mechanisms, non-coding RNAs, such as TERRA, have also been implicated in the regulation of telomere length. TERRA interacts with telomeric DNA and can recruit proteins that influence telomere maintenance.
Ultimately, the negative regulation of telomeric DNA binding ensures that telomeres are maintained at appropriate lengths and that cells do not proliferate uncontrollably. Dysregulation of this process can have serious consequences for cellular function and organismal health.'
"
Protein | Definition | Taxonomy |
---|---|---|
Poly [ADP-ribose] polymerase tankyrase-1 | A poly [ADP-ribose] polymerase tankyrase-1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O95271] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
4'-bromoflavone | 4'-bromoflavone: structure in first source | ||
phenanthridone | phenanthridone : A member of the class of phenanthridines that is phenanthridine with an oxo substituent at position 6. A poly(ADP-ribose) polymerase (PARP) inhibitor, it has been shown to exhibit immunosuppressive activity. phenanthridone: coal tar derivative; structure given in first source | lactam; phenanthridines | EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; immunosuppressive agent; mutagen |
pj-34 | PJ34 : A member of the class of phenanthridines that is 5,6-dihydrophenanthridine substituted at positions 2 and 6 by (N,N-dimethylglycyl)amino and oxo groups, respectively. It is a potent inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 (IC50 of 110 nM and 86 nM, respectively) and exhibits anti-cancer, cardioprotective and neuroprotective properties. | phenanthridines; secondary carboxamide; tertiary amino compound | angiogenesis inhibitor; anti-inflammatory agent; antiatherosclerotic agent; antineoplastic agent; apoptosis inducer; cardioprotective agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; neuroprotective agent |
flavone | flavone : The simplest member of the class of flavones that consists of 4H-chromen-4-one bearing a phenyl substituent at position 2. flavone: RN given refers to unlabeled cpd; structure given in first source | flavones | metabolite; nematicide |
4-Methoxybenzamide | benzamides | ||
4'-methoxyflavone | 4'-methoxyflavone: from seeds of Psoralea corylifolia (Fabaceae); structure in first source | ether; flavonoids | |
3',4'-dihydroxyflavone | 3',4'-dihydroxyflavone: inhibitors of arachidonic acid peroxidation | ||
3-methoxyflavone | 3-methoxyflavone: from Aspergillus niger; structure in first source | ||
2'-methoxyflavone | ether; flavonoids | ||
6-methoxyflavone | 6-methoxyflavone: suppresses NFAT-mediated T cell activation; structure in first source | ether; flavonoids | |
4'-chloroflavone | 4'-chloroflavone: structure given in first source | ||
4'-hydroxyflavone | 4'-hydroxyflavone: structure in first source | ||
6-chloroflavone | 6-chloroflavone: structure in first source | ||
e-z cinnamic acid | cinnamic acid : A monocarboxylic acid that consists of acrylic acid bearing a phenyl substituent at the 3-position. It is found in Cinnamomum cassia. trans-cinnamic acid : The E (trans) isomer of cinnamic acid | cinnamic acid | plant metabolite |
7-methoxyflavone | 7-methoxyflavone: an aromatase inhibitor | ether; flavonoids | |
6-methylflavone | 6-methylflavone: structure in first source | ||
N-(3-methylphenyl)-4-tetrazolo[1,5-a]quinoxalinamine | quinoxaline derivative | ||
iwr-1 exo | IWR-1-exo : A dicarboximide having an exo bridged phthalimide structure, substituted at nitrogen by a 4-(quinolin-8-ylcarbamoyl)benzoyl group. It is a weak axin stabilizer, an analogue of IWR-1-endo. | bridged compound; dicarboximide | axin stabilizer |
N-[4-[[[4-(4-methoxyphenyl)-4-oxanyl]methylamino]-oxomethyl]phenyl]-2-furancarboxamide | aromatic amide; furans | ||
apigenin | Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia. | trihydroxyflavone | antineoplastic agent; metabolite |
luteolin | 3'-hydroxyflavonoid; tetrahydroxyflavone | angiogenesis inhibitor; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; c-Jun N-terminal kinase inhibitor; EC 2.3.1.85 (fatty acid synthase) inhibitor; immunomodulator; nephroprotective agent; plant metabolite; radical scavenger; vascular endothelial growth factor receptor antagonist | |
3',4',7-trihydroxyflavone | 3',4',7-trihydroxyflavone: from the Sudanese medicinal plant Albizia zygia; structure in first source | flavones | |
rucaparib | AG14447: Poly(ADP-ribose) polymerase inhibitor; structure in first source | azepinoindole; caprolactams; organofluorine compound; secondary amino compound | antineoplastic agent; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor |
veliparib | benzimidazoles | EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | |
N-(4-methylphenyl)-4-tetrazolo[1,5-a]quinoxalinamine | quinoxaline derivative | ||
olaparib | cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines | antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | |
niraparib | niraparib : A 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide that has S-configuration. It is a potent inhibitor of PARP1 and PARP2 (IC50 of 3.8 and 2.1 nM, respectively) and approved as a first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy. niraparib: structure in first source | 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide | antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; radiosensitizing agent |
iwr-1 endo | IWR-1-endo : A dicarboximide having an endo bridged phthalimide structure, substituted at nitrogen by a 4-(quinolin-8-ylcarbamoyl)benzoyl group. | benzamides; bridged compound; dicarboximide; quinolines | axin stabilizer; Wnt signalling inhibitor |
nms-p118 | NMS-P118: a PARP-1 inhibitor; structure in first source | ||
g007-lk | G007-LK: potent and specific small-molecule tankyrase inhibitor; structure in first source | ||
CCT251545 | CCT251545 : A chloropyridine that is 3-chloropyridine substituted by a 1-oxo-2,8-diazaspiro[4.5]decan-8-yl group and a 4-(1-methyl-1H-pyrazol-4-yl)phenyl group at positions 4 and 5, respectively. It is an orally bioavailable inhibitor of Wnt signaling (IC50 = 5 nM) and a potent and selective chemical probe for cyclin-dependent kinases CDK8 and CDK19. CCT251545: a Wnt signaling inhibitor; structure in first source | azaspiro compound; chloropyridine; pyrazoles | antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; Wnt signalling inhibitor |
xav939 | XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group. XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source | (trifluoromethyl)benzenes; thiopyranopyrimidine | tankyrase inhibitor |
2-(4-methoxyphenyl)-1H-quinazolin-4-one | quinazolines | ||
bmn 673 | talazoparib: inhibits both PARP1 and PARP2; structure in first source |